Browsing Tag
immuno-oncology
30 posts
How orphan drug status and patent protection shape Ampligen’s commercial and regulatory outlook
Discover how orphan drug status and long-dated patents could shape Ampligen’s regulatory path and commercial value in pancreatic cancer.
How SC-dosed NK cell engagers like GTB-5550 could disrupt cancer care delivery models
GT Biopharma’s GTB-5550 receives FDA clearance with subcutaneous delivery. See how this trial could shift NK immunotherapy into outpatient cancer care.
NK cell immunotherapy moves toward solid tumors as GT Biopharma files IND for GTB-5550 TriKE
Find out how NK cell immunotherapy is moving into solid tumors as GT Biopharma files an IND for its B7-H3-targeted TriKE GTB-5550.
Senhwa Biosciences strikes pivotal supply deal with BeOne Medicines for cold tumor breakthrough
Senhwa Biosciences and BeOne Medicines announce a global clinical trial to tackle cold tumors. Find out how this deal could change cancer immunotherapy.
Why Imugene is using a virus to “mark” tumors for CAR-T attack—and what JW Therapeutics brings to the table
Find out how Imugene and JW Therapeutics plan to make solid tumors respond to CD19 CAR-T therapy using an oncolytic virus strategy.
Mural Oncology shareholders to receive fixed $2.035 per share as XOMA Royalty deal nears closing
Mural Oncology confirms a fixed $2.035 per share cash payout as its acquisition by XOMA Royalty nears closing, locking in a definitive exit for investors.
Investors eye PHIO as Phio Pharmaceuticals reports full Phase 1b enrollment and strong preliminary PH-762 results
Find out how Phio Pharmaceuticals’ PH-762 trial progress and early response signals could reshape RNA-based cancer therapies.
Can immunotherapy finally replace chemo in bladder cancer? Keytruda–Padcev combo shows the way
Explore how Merck’s Keytruda and Padcev combo is redefining bladder cancer treatment without chemo. Survival gains, sector impact, and what’s next in focus.
Metastatic TNBC sees unexpected remission as Kazia Therapeutics’ Q4 update reveals pipeline momentum across cancer programs
Learn how Kazia Therapeutics’ rare iCR in metastatic TNBC is reshaping its breast cancer, immuno-oncology, and GBM pipeline strategy.
Caribou Biosciences set for key webcast showcasing CRISPR-engineered CAR-T breakthroughs in blood cancers
Discover how Caribou Biosciences is preparing to reveal breakthrough CRISPR-edited allogeneic CAR-T data in lymphoma and myeloma during its investor webcast.